TCT Meetings Symposium

TCT Meetings Symposium

Strategies for Dodging the Obstacles in CAR T Cell Therapy

CAR T cell therapy has experienced its ups and downs in terms of toxicities and efficacy shortcomings.

Frontiers in Oncology
CAR T Cell Therapy Shows Benefits in Patients With R/R Indolent Non-Hodgkin Lymphoma

Per results presented at the 2021 TCT Meetings, the autologous anti-CD19 CAR T-cell therapy axicabtagene ciloleucel (axi-cel) yields considerable and durable clinical benefits.

The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma

Study investigators construct the BCMA-targeted fourth-generation CAR-T cells expressing IL-7 and CCL19, and demonstrate that BCMA-7 × 19 CAR-T cells exhibit...

Frontiers in Immunology

Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia in Japan

The objective of this study is to assess the cost-effectiveness of a tisagenlecleucel treatment strategy compared to a  blinatumomab treatment strategy and a clofarabine combination...

Transplantation and Cellular Therapy
Efficacy and Safety of Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Immunoglobulin D Multiple Myeloma

This study is designed to investigate efficacy and safety of chimeric antigen receptor T-cell therapy for relapsed/refractory IgD MM (R/R IgD MM).

Transplantation and Cellular Therapy
Anakinra Shows Promise as Steroid-Sparing Agent for CAR T-Cell Therapy-Related Toxicities

Steroids are commonly used to mitigate severe treatment-related adverse events associated with chimeric antigen receptor T-cell therapy.

CAR T-Cell Therapy ‘Extremely Effective’ for Advanced Follicular Lymphoma, Early Data Show

Sixty-five percent of patients with R/R FL had an initial complete response to a single infusion of tisagenlecleucel, according to phase 2 study results presented at TCT Meetings Digital Experience

Anti-CD22 CAR T-Cell Therapy A ‘Promising Option’ for Advanced B-Cell Malignancies

An investigational CAR T-cell therapy appears safe and demonstrates antitumor activity among patients with R/R B-cell malignancies, according to results presented at TCT Meetings Digital Experience

Higher CAR-T Dose Associated With Longer Remission Among Younger Patients With ALL

Children and young adults with ALL who received higher doses of tisagenlecleucel achieved significantly longer OS and RFS, according to study results presented at TCT Meetings Digital Experience.

CARs Are the Ride of the Future for Curing DLBCL

Chimeric antigen receptor T-cell therapy has the potential to cure the most diffuse large B-cell lymphoma patients who have recurrent disease.

Oncology Times - Latest Articles
First CAR T-Cell Therapy for Multiple Myeloma: Abecma

CAR T-cell therapy, described as a "living drug," is now available for patients with relapsed/refractory multiple myeloma who have been treated with four or more prior lines of therapy.

Long-Term Follow-Up of CD19-CAR T-Cell Therapy in Children and Young Adults With B-ALL

Study investigators conduct a phase I trial of autologous CD19.28ζ-CAR T cells in CAYAs with relapsed or refractory B-ALL.

Journal of Clinical Oncology
‘On-Your-Toes’ Approach to Managing Infection Risk Needed as CAR T-Cell Therapy Evolves

Chimeric antigen receptor T-cell therapy employs a patient’s immune system to fight cancer and thereby weakens it, leaving the recipient vulnerable to infection.

Outpatient CAR T-Cell Therapy Safe, Effective for Advanced Large B-Cell Lymphoma

Patients with relapsed or refractory large B-cell lymphoma who received lisocabtagene maraleucel had similar response rates regardless of the type of center providing the CAR T-cell therapy.

CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma

Lisocabtagene maraleucel, marketed as Breyanzi, is a CAR-T therapy indicated for patients who haven’t responded to or have relapsed after at least 2 other systemic treatments.

JAMA Network
Tear Lipid Metabolites As Potential Diagnostic Biomarkers for Ocular Chronic Graft-Versus-Host Disease

cGVHD remains a common threat after allo-HSCT, and ocular manifestations occur in up to 60% to 90% of cGVHD patients.

Pretransplantation MRD in Older Patients With AML After Treatment With Decitabine or Conventional Chemotherapy

This retrospective analysis includes patients ≥60 years of age with AML who received an alloHCT after treatment with decitabine or intensive chemotherapy. 

CAR T-Cell Therapy: Current Practice and Future Solutions to Optimize Patient Access

This review article will address these clinical and financial challenges and provide solutions to optimize CAR-T cell therapy’s framework toward expanding access.

Journal of Clinical Pathways

source list reference